Background: There are varying reports of the association of basal cell carcinoma (BCC) and cutaneous squamous cell carcinoma (SCC) with mortality.
Basal cell carcinoma (BCC) and cutaneous squamous cell carcinoma (SCC) are, taken together, the most common cancers in the United States and commonly affect older white individuals. 1 Some populations of patients, such as organ transplant recipients, are at significantly increased risk for death from BCC and SCC. 2 In the general population, however, deaths from BCCs and SCCs do not have a large impact on mortality: for example, age-adjusted morality rates for SCC are reported at approximately 1 per 100,000 person-years or less, [3] [4] [5] [6] compared with mortality rates of 205 per 100,000 person-years for heart disease or 180 per 100,000 person-years for cancer overall in the United States. 7 It is unclear, however, whether typical patients with a history of BCC or SCC have different risk for death from any cause compared with the general population.
Several recent studies suggest an increased risk for second primary cancers (including breast cancer, lung cancer, leukemia, and melanoma) among individuals with BCC and SCC when compared with those without. [8] [9] [10] [11] [12] [13] [14] [15] [16] Additionally, there are growing data that the genetic features seen in these cancers, including shortened telomeres and defective DNA repair, are associated with myocardial infarction and stroke. [17] [18] [19] [20] [21] [22] Yet the few studies to evaluate all-cause mortality after a diagnosis of these skin cancers have shown mixed results. 14, [23] [24] [25] [26] [27] Several studies have grouped patients with BCC and SCC together, and some have concluded that patients with either BCC or SCC have a decreased risk for death, 26 whereas others have concluded that these patients have an increased risk for death. 27 Estimates from studies that separated patients with BCC from those with SCC have suggested that SCC is associated with decreased survival, whereas BCC has been associated with equal or increased survival compared with that for the general population. 23, 25, 28 Understanding the risk for death among patients with skin cancer is important for 2 reasons: (1) providing a better understanding of disease pathogenesis in the context of recent studies suggesting that skin cancers may be independent risk factors and markers of cancer-prone genetic phenotypes 29, 30 and (2) improving clinical care and prevention recommendations for these patients.
The aim of this study was to synthesize the available information on the risk for all-cause mortality after a diagnosis of BCC or cutaneous SCC.
MATERIALS AND METHODS
This systematic review and meta-analysis was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-analyses and MetaAnalysis of Observational Studies in Epidemiology guidelines. 31, 32 Literature search
Studies were identified through searches of electronic databases and by scanning reference lists of articles. We searched Embase (1947-present), PubMed (1966-present) , and Web of Science (1898-present). Two authors (W.C.S. and M.R.W.) performed the search; the final search was run on February 21, 2016. Additionally, we reviewed articles and reviews on the topics of BCC and SCC and all-cause mortality closely to locate additional articles. The search strategies used for each database are available in the Supplemental Materials (available at http://www. jaad.org).
All published articles in English that reported allcause mortality or survival in patients with BCC and/ or SCC were eligible for inclusion. Study eligibility was assessed by 2 authors using title and abstract for initial screening (M.R.W. and W.C.S), followed by full-text review by 3 authors (M.R.W., W.C.S., and A.N.). Any disagreements were settled by a fourth author (E.L.). We excluded articles that presented no data (review articles and editorials), as well as case reports and case series. We also excluded articles that presented data on only a subpopulation of patients (eg, patients with xeroderma pigmentosum, organ transplant recipients, patients with SCC of the lip), which might have increased risk for all-cause mortality compared with that for all-comers with BCC and SCC. Studies that reported an effect estimate of mortality or survival for BCC and SCC separately were eligible for inclusion in quantitative metaanalysis. Studies with study population overlap were excluded from quantitative meta-analysis but were included in qualitative review if they provided additional qualitative value.
Three authors (M.R.W., W.C.S., and E.L.) discussed the studies with population overlap to
CAPSULE SUMMARY d
There are varying reports of the association of basal cell carcinoma or cutaneous squamous cell carcinoma (SCC) with all-cause mortality. determine which to include. Of the 7 studies from Denmark that individually the met inclusion criteria, 5 reported data from the Danish Cancer Registry (DCR), 25, 26, [33] [34] [35] 1 reported data from the Gerda Frentz cohort (GFC), 36 and 1 used both DCR and GFC data. 37 Approximately 35% of patients in the GFC, however, are also found in the DCR. Of these 7 studies that analyzed overlapping data, we included that by Jensen et al 25 for quantitative analysis because it had the larger study population. Additionally, we included both the study by Brondum-Jacobsen et al 26 and that by Jensen et al 33 in the qualitative portion of our review despite the population overlap because they provided complementary information: Brondum-Jacobsen et al 26 provided an effect estimate for BCC and SCC combined, and Jensen et al 33 compared SCC and BCC cases with sex-matched controls and adjusted for socioeconomic status and comorbidities, as many other studies did not. There were also 2 studies with overlapping data from the Cancer Registry of Norway, 38, 39 and we included the larger of the 2.
38
Data were extracted from articles by using a data extraction sheet that was developed on the basis of the Cochrane Consumers and Communication Review Group's data extraction template. 40 We extracted the following items for each study: characteristics of the study participants (including age, sex, BCC/SCC status, and comorbidities), participant inclusion/exclusion criteria, sources of mortality and BCC/SCC diagnosis, characteristics of study design (including design type, and presence and characteristics of matching or standardization), statistical methods (including analysis type and variables included), and all-cause mortality or survival outcomes for BCC and/or SCC.
Statistical methods
Hazard ratios, odds ratios, standardized mortality ratios, mortality rate ratios, and relative risks were considered equivalent measures of risk. 41, 42 Relative mortality estimates, such as standardized mortality ratios (SMRs), were published for 3 of the studies included in the quantitative analysis. One SMR estimate was obtained from the authors of a study that assessed survival in patients with BCC and SCC but did not include relative mortality estimates in the original article. 6 One SMR was calculated from the numbers of observed and expected surviving patients provided in an article. 43 We used Stata 12 software (StataCorp LP, College Station, TX) to perform random effects model metaanalysis, yielding summary relative risks and 95% confidence intervals (CIs). We analyzed the data for BCC and SCC separately. To investigate heterogeneity in study outcomes, we used a x 2 test for heterogeneity and an I 2 statistic. We did not statistically assess the potential for small study effects or publication bias, as both of our analyses had 4 or fewer studies included.
RESULTS

Fig 1
shows the study selection process. Database and hand searches yielded a total of 6538 unique publications that were screened by title and abstract. A total of 156 articles were assessed for eligibility in a full-text review; 144 articles were excluded because of no relevance (n = 49), reporting of disease-specific rather than all-cause mortality (n = 38), inclusion of only subpopulations (n = 19), no original data (n = 16), language other than English (n = 12), duplicate study populations (n = 9), and being a case series (n = 1).
In all, 12 studies met the inclusion criteria. Table I 6,23,25-28,33,43-46 summarizes the study characteristics of these 12 studies. Table II 6,25-28,33,38, [43] [44] [45] [46] details the outcome measures, effect estimates, and statistical adjustments for the 12 included studies. We included 4 studies in the quantitative meta-analysis. Excluded from the meta-analysis were studies grouping patients with BCC and SCC, 26 ,27 studies reporting effect estimates that could not be converted to a relative mortality measure, 23, 38, [44] [45] [46] [47] studies with population overlap, 26, 33 1 study that evaluating ''malignant skin cancer, excluding melanoma'' in a cancer registry that did not include BCC, 46 and 1 study that did not detail CIs or standard errors for its relative survival estimates. 45 The studies included in the metaanalysis analyzed data collected between1973 and 2011 in 4 different countries and represented a total of 464,230 patients with BCC and 175,849 patients with SCC.
Qualitatively, 2 studies evaluated relative mortality of BCC and SCC combined: 1 showed slightly increased mortality, 27 and 1 showed slight decreased mortality, 26 both of which were statistically significant. 26, 27 In patients with BCC, 3 studies included in quantitative meta-analysis showed effect estimates consistent with decreased relative mortality, 25,28,43 2 of which were statistically significant. 25, 43 One study in the qualitative review reported relative survival rates that indicated slightly increased mortality in men and slightly decreased mortality in women but did not report statistical significance. 23 Another study in the qualitative review, which had an overlapping population with a study included in quantitative metaanalysis 25 but adjusted for 23 comorbidities and socioeconomic status, reported a statistically significant decreased mortality rate ratio. 33 The random effects meta-analysis of 3 studies 25, 28, 43 yielded a summary relative risk of 0.92 (95% CI, 0.83-1.02) (Fig 2) . 45, 46 For quantitative meta-analysis, we were able to include effect estimates for relative mortality from 4 studies. 6, 25, 28, 43 A random effects metaanalysis yielded a summary relative risk of 1.25 (95% CI, 1.17-1.32) (Fig 3) . The x 2 test for heterogeneity yielded a P value less than .001 and an I 2 statistic of 98.8%.
DISCUSSION
In our qualitative systematic review we found no significant difference in risk for all-cause mortality in patients with BCC (relative mortality estimates Sweden, 2004 Sweden, 1960 Sweden, -1998 Retrospective cohort using national registries
BCC, Basal cell carcinoma; F, female; KC, keratinocyte carcinoma (BCC and SCC grouped together in publication); M, male; SCC, squamous cell carcinoma; SD, standard deviation. *Number of deaths was calculated by using percentage of surviving patients presented in the article. y Jensen et al, 25 Brondum-Jacobsen et al, 26 and Jensen et al 33 have overlapping study populations. Brondum-Jacobsen et al 26 was included qualitatively because it provides a combined BCC/SCC estimate. Jensen et al 33 was included qualitatively because it adjusted extensively for covariates. z Included ''malignant skin cancer excluding melanoma'' in a cancer registry that does not collect BCC data. showed decreased mortality or null effects). Conversely, we found consistently increased relative all-cause mortality in patients with a history of SCC. According to a quantitative meta-analysis including a total of 464,230 patients with BCC and 175,849 patients with SCC, we found that patients with SCC have statistically significantly higher (approximately 25%) all-cause mortality compared with the general population. Our findings add to the published literature by clarifying that there may be a different pattern of allcause mortality in patients with BCC compared with that in patients with SCC. Because these tumors often occur in the same patients and are both often caused by exposure to ultraviolet radiation, patients with BCC and SCC are often grouped together and considered to have nonmelanoma skin cancers or keratinocyte carcinomas. Our data contribute to the argument that the carcinogenesis of these tumors and long-term outcomes for patients with these tumors may be distinct.
Studies that combine BCC and SCC have found varying results in relation to mortality: BrondumJacobsen et al 26 showed a decreased mortality whereas Kahn et al 27 showed a potentially increased mortality (not statistically significant). Although no study has directly compared patients with BCC and those with SCC, studies that separate BCC and SCC consistently report different relative survivals. In our systematic review, we found that most studies reported a decreased mortality or no statistically significant effect in patients with history of BCC. 23, 25, 28, 33, 43 In patients with a history of SCC, on the other hand, every study reported an effect estimate of increased mortality, though some of these were not tested for statistical significance. 23, 25, 28, 33, 37, 43, 45, 46 The higher risk for death from any cause in patients with a history of SCC may be related to common risk factors, which our study was not able to investigate. Only 2 of the 12 studies in this review controlled for medical comorbidities, 27, 33 neither of which was included in the quantitative analysis. SCC is associated with immunosuppression, which increases the risk for multiple negative health outcomes such as infection and cancer. There is also some evidence that SCC may be associated with smoking, 25, 48 which increases the risk for cardiovascular disease and other cancers. 14, 24, [49] [50] [51] In addition, indoor tanning behaviors, which are associated with BCC and SCC, 52 are associated with other high-risk health behaviors such as smoking, alcohol use, and drug use. [53] [54] [55] BCC and SCC have also been associated with increased risk for subsequent cancer, including breast cancer, lung CI, Confidence interval; cml, cumulative; F, female; HR, hazard ratio; M, male; MRR, mortality rate ratio; OR, odds ratio; RR, relative risk; RSR, relative survival rate; SCC, squamous cell carcinoma; SD, standard deviation; SE, standard error; SMR, standardized mortality ratio. *SMR calculated by using absolute and relative 10-year survival data reported in article. J AM ACAD DERMATOL VOLUME 78, NUMBER 4 cancer, leukemia, and melanoma. [8] [9] [10] [11] [12] [13] [14] [15] [16] It is important to note that although SCC is associated with other factors that may be driving this increased mortality, the studies we included examined the broader general population of patients with BCC and SCC without limitation to groups with specific comorbidities. Thus, our findings may be generalizable to allcomers with these common skin cancers.
This study is limited by the fact that it included mainly retrospective observational studies; only 1 of the studies was a prospective cohort study. 44 Our quantitative analysis was limited by the variation in summary measures of mortality and survival data studies reported, some of which we were not able to convert to a relative mortality measure and include in our analysis. Statistical limitations include the significant heterogeneity noted in both our quantitative meta-analyses. Although random-effects methodology is the appropriate choice for heterogeneous data, the included studies may have significant clinical or methodologic differences and care should be taken when using the summary estimate from this study. Some potential sources of heterogeneity that we identified were study design (1 cohort study 28 was derived from a previous case-control study whereas the rest were national registry cohorts), location (the United States, Germany, Denmark, and the Netherlands were represented in these analyses), and the lack of adjustment for potential confounders (all 4 used age and sex, 6 ,25,28,43 2 used calendar period, 6 ,25 and 1 used smoking and subsequent cancer diagnosis, 28 but no other comorbidities were included). Despite this, the vast majority of studies included showed results similar to the summary estimates, and the studies of SCC in particular were all qualitatively concordant with increased relative mortalities. Therefore we believe that estimating a summary effect through metaanalysis is both useful and methodologically appropriate. Additionally, none of the included studies reported SCC-specific or BCC-specific mortality. Although the published literature on mortality rates of SCC indicates that the relative contribution of the SCCs themselves to the excess mortality we observed for SCC is likely small, we were not able to explore this further. [3] [4] [5] [6] 56 Finally, we were unable to put our findings in context with other cancers. The studies included in quantitative analysis reported all-cause mortality ratios (eg, SMRs), which are difficult to compare with typical measures of mortality (eg, rates) in other cancers. For example, SEER reports the 5-year relative mortality rate for melanoma at 8.5%, 57 which cannot be directly compared with our finding of an increased relative mortality ratio of 1.25 for SCC.
This study supports the growing literature that identifies BCC and SCC as distinct neoplasms with different histology, pathophysiology, and outcomes, including all-cause mortality. Patients with SCC are at increased risk for death from any cause compared with the general population, whereas patients with BCC may not have increased all-cause mortality. We believe that our findings have clinical implications for patients with SCC, who may need additional education and age-appropriate screening to prevent death from major diseases. Although many patients get both BCC and SCC, future research should take into account that these cancers may have different long-term risks and outcomes.
